Promius Pharma, which will initially focus on the branded dermatology market, is said to be based on a platform of strategic licensing initiatives and internal product development activities undertaken over the last several years.
Promius Pharma’s product portfolio currently comprises of three in-licensed and co-developed dermatological products that are scheduled to launch within calendar years 2008-09, and a pipeline of topical products being developed at the integrated product development facility in Hyderabad, India.
Promius Pharma’s current portfolio contains topical products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis.
GV Prasad, vice chairman and CEO of Dr Reddy’s, said: “We are pleased to announce Promius Pharma, our US specialty business, a meaningful milestone in our overall strategy of building a sustainable and profitable branded business. We are committed to establishing a leading position in the US dermatology market by providing innovative solutions to patients and physicians that leverage Promius Pharma’s current portfolio and future additions.”